2. Academic Validation
  3. Design, synthesis and biological evaluation of 2-mercapto-3-phenethylquinazoline bearing anilide fragments as potential antitumor agents: molecular docking study

Design, synthesis and biological evaluation of 2-mercapto-3-phenethylquinazoline bearing anilide fragments as potential antitumor agents: molecular docking study

  • Bioorg Med Chem Lett. 2013 Jul 1;23(13):3935-41. doi: 10.1016/j.bmcl.2013.04.056.
Ibrahim A Al-Suwaidan 1,  Amer M Alanazi,  Alaa A-M Abdel-Aziz,  Menshawy A Mohamed,  Adel S El-Azab
Affiliations

Affiliation

  • 1 Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.
PMID: 23683592 DOI: 10.1016/j.bmcl.2013.04.056
Abstract

A novel series of 2-(3-phenethyl-4(3H)quinazolin-2-ylthio)-N-substituted anilide and substituted phenyl 2-(3-phenethyl-4(3H) quinazolin-2-ylthio)acetate were designed, synthesized and evaluated for their in-vitro antitumor activity. Compound 15 possessed remarkable broad-spectrum antitumor activity which almost sevenfold more active than the known drug 5-FU with GI50 values of 3.16 and 22.60 μM, respectively. Compound 15 exhibited remarkable growth inhibitory activity pattern against renal Cancer (GI50=1.77 μM), colon Cancer (GI50=2.02 μM), non-small cell lung Cancer (GI50=2.04 μM), breast Cancer (GI50=2.77 μM), ovarian Cancer (GI50=2.55 μM) and melanoma Cancer (GI50=3.30 μM). Docking study was performed for compound 15 into ATP binding site of EGFR-TK which showed similar binding mode to erlotinib.

Figures